A survival benefit for imatinib mesylate versus interferon-α therapy could not be demonstrated in the randomized study in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML) due to the high rate of cross over (90%) from interferon-α to imatinib within a year of study entry. We compared survival in 279 patients with newly diagnosed CML treated with imatinib at our institution (2000 -2004) to 650 patients treated with interferon-α (1982 -1997). The complete cytogenetic response rates were 87% with imatinib and 28% with interferon-α (p < 0.0001). The estimated 3-year survival rates were 96% with imatinib and 81% with interferon-α (p < 0.01).
Survival rates with imatinib were significantly better than with interferon-α within each of the CML prognostic risks groups. By multivariate analysis, imatinib therapy was identified as an independent favorable prognostic factor, after accounting for the impact of pretreatment factors (hazard ratio 0.04; p < 0.01).
By landmark analysis at 12 months, survival within each cytogenetic response category was similar with imatinib or interferon-α, suggesting that the survival benefit of imatinib (versus interferon-α in newly diagnosed CML) is through improving cytogenetic response. interferon-α crossed over to imatinib after a median of 9 months from start of study, thus benefiting from imatinib therapy early into their disease. 2 Additional randomized studies of imatinib versus previous standard strategies are unlikely to be performed. A survival advantage for imatinib therapy can then be demonstrated only through careful comparative studies with precisely defined historical control populations treated with interferon-α based regimens. This is the purpose of this study which confirms, with long-term followup, the survival advantage of imatinib therapy versus interferon-α in newly diagnosed CML. Adults with newly diagnosed Ph-positive early chronic phase CML (ie, within 6 months from diagnosis) treated at our institution from July 2000 until December 2004 with imatinib were analyzed. These patients were treated on frontline therapies with imatinib 400 mg orally daily (n = 73), 600 mg orally daily (n = 12) or 800 mg orally daily (400 mg orally twice daily, n = 194). Their survival by imatinib dose was identical, justifying their inclusion as one treatment group for comparative survival analysis. The minimum follow-up time of these patients was longer than 12 months. Their outcome was compared to 650 patients treated on interferon-α regimens from 1982 to1997. Interferon-α regimens included: interferon-α alone or with hydroxyurea (n = 270), interferon-α + low dose cytarabine (n = 285), and interferon-α + homoharringtonine (n = 95). [4] [5] [6] Survivals in different studies containing interferon-α were similar, justifying their inclusion as one treatment category for the purpose of comparative analysis with imatinib. The median follow-up times with imatinib regimens was 42 months (range 12 to 66 months), and with interferon-α regimens 143 months (range 4 to 270 months). All patients signed informed consents for the respective protocols according to institutional guidelines. Eligibility criteria were similar on all studies, and the details of the therapies were previously reported. [3] [4] [5] [6] Response criteria were as published. 4 
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PATIENTS AND METHODS
RESULTS
Two hundred seventy-nine patients treated with imatinib were compared to 650 patients who received interferon-α. The significant pretreatment characteristics of the imatinib and interferon-α groups are detailed in Table 1 .
Patients on imatinib therapy were older and had a higher incidence of marrow basophilia. Patients on interferon-α therapy had higher incidences of leukocytosis, and thrombocytosis, and a longer duration of CML disease (Table   1) . One hundred forty-one patients (22%) on IFN-α therapy changed to imatinib Response with imatinib versus interferon-α.
The complete cytogenetic response rate was 87% with imatinib and 28% with interferon-α ( Table 2 ). The incidence of complete cytogenetic response with imatinib or interferon-α within each risk group is shown in Table 2 Within each risk group, imatinib was associated with a significantly better survival than interferon-α.
Since some characteristics of patients treated with imatinib versus interferon-α were different, we conducted univariate then multivariate analyses of pretreatment factors associated with survival in the total study group of 929 patients treated with either imatinib or interferon-α. The univariate analysis selected the following poor prognostic factors (p < 0.05): older age, splenomegaly, leukocytosis, higher blast percent, higher basophil percent, CML risk group, and longer duration of CML (Table 3 ). The multivariate analysis selected the following to be independent poor prognostic factors: older age (p = 0.01), higher peripheral blast percent (p < 0.01), increased marrow basophils (p = 0.01), and longer CML disease duration (p < 0.01). Therapy (imatinib versus interferon-α), entered into the model after accounting for the effect of the independent pretreatment factors, remained a significant independent factor favoring imatinib therapy (hazard ratio 0.44, p value < 0.01).
For
Outcome with imatinib by response at 12 months into therapy.
Response to imatinib therapy after one year of exposure may help define prognosis and the need for treatment modification. Figure 3A shows the outcome of patients by cytogenetic response at 12 months. Patients who did not achieve a major cytogenetic response by that time had a worse survival than others (estimated 3-year survival 99% versus 84%; p = 0.0003). The estimated 3-year survival rates were 98% for complete cytogenetic response (n = 210) and 100% for partial cytogenetic response (n = 21). The estimated 5-year survival rates were 94% in both cytogenetic subgroups. Survival of patients in complete cytogenetic response at 12 months was not different by whether they achieved a major molecular response or not ( Figure 3B) . Similarly, transformation-free survival was not different (estimated 3-year rates 98% with major molecular response versus 95% for others; p = 0.28), nor was progression-free survival (estimated 3-year rates 98% versus 94%; p = 0.14). 14 In contrast to the study of Roy et al, our study included patients on However, since survival by imatinib dose is similar (Table 3) and survival by different interferon-regimens also similar, the comparative analysis of the two treatment groups (imatinib versus interferon-α) is reasonable. Also, although 22% of patients on interferon-α crossed-over to imatinib, this occurred quite late (median time to cross over 84 months) and would not affect the comparative survival analysis in the first 3 to 5 years. Censoring these 22% of patients on interferon-α at the time of treatment cross-over also yielded identical results.
Thus, despite the differences between the study groups in the analysis of Roy et al 14 and ours, the very similar results in the two studies further strengthen the conclusion that imatinib therapy offers a significant survival advantage over interferon-α therapy.
As in previous studies, the 12 month cytogenetic response to imatinib was predictive of prognosis. 2, 12 Patients who had achieved less than a major cytogenetic response had a worse prognosis ( Figure 3A) . However, among patients achieving a complete cytogenetic response, the degree of molecular response at 12 months was so far not associated with significant differences in survival, transformation-free survival, or progression-free survival (Figure 4 
B).
This is in contrast to the recently updated IRIS results showing a difference in transformation-free survival by the degree of molecular response. 13 This may be due to differences in the imatinib dose schedules, definitions of major molecular response and failure, QPCR methodologies, size of the study groups and nature of the analysis. In particular, the IRIS study included a larger number of patients
org From
Page 11 of 27 treated with imatinib (n = 551) compared with our study (n = 279), and the IRIS study was prospective in nature, while this analysis is a retrospective one.
An important issue is whether imatinib can improve survival independent of cytogenetic response. This study shows that the survival benefit in newly diagnosed CML (compared with interferon-α) with imatinib is through improving cytogenetic responses. This is different from the results of imatinib versus other therapies in late chronic phase post interferon-α failure CML, 14 which showed better survival with imatinib within each cytogenetic response category. For For personal use only. on October 3, 2017. by guest
